Premium
L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma
Author(s) -
Tsutsumi Shinji,
Morohashi Satoko,
Kudo Yasuyuki,
Akasaka Harue,
Ogasawara Hiroshi,
Ono Masashi,
Takasugi Kaori,
Ishido Keinosuke,
Hakamada Kenichi,
Kijima Hiroshi
Publication year - 2011
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21880
Subject(s) - medicine , pancreatic ductal adenocarcinoma , l1 , cell adhesion molecule , pathology , adenocarcinoma , pancreatic cancer , cancer , oncology , cancer research , immunology , human papillomavirus
Background and Objectives Pancreatic ductal adenocarcinoma (PDAC) is one of the most extremely aggressive cancers with a poor prognosis after curative resection. L1 cell adhesion molecule (L1CAM) is a 200–220 kDa type I transmembrane glycoprotein of the immunoglobulin superfamily, which has been shown to affect the prognosis of several cancers. No clinicopathological significance of L1CAM expression has been examined at the invasive front of PDAC. In this study, we examined the relationship between L1CAM expression and clinicopathological features in PDAC by immunohistochemistry. Methods One hundred seven surgically resected specimens of PDAC were immunohistochemically examined using a monoclonal antibody against L1CAM. Results Positive expression of L1CAM was found in 23 of 107 cases with PDAC. In most cases (21/23), L1CAM expression was localized at the invasive front of the tumor tissue. Positive expression of L1CAM was significantly correlated with the histological grade, lymph node involvement, and distant metastasis. In univariate analysis, a positive expression of L1CAM was associated with short overall survival ( P = 0.0002), and this was significant in multivariate analysis ( P = 0.009). Conclusions L1CAM could play an important role in the invasive process in vivo, and is thought to be a good indicator of prognosis in PDAC. J. Surg. Oncol. 2011;103:669–673. © 2011 Wiley‐Liss, Inc.